Orthometrix, Inc.

Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fasciitis, and other musculoskeletal conditions that reduce mobility. The company markets, sells, and services peripheral quantitative computed tomography bone and muscle measurement systems for research and clinical applications; patented motorized exercise systems for rehabilitation, physical therapy, and sports medicine based on patented vibration technology; human performance measurement systems for monitoring improvement in power and mobility; and extracorporeal shock wave therapy systems for non-invasive treatment of pain associated with plantar fasciitis. It also markets, sells, and services patented motorized exercise systems to professional teams, fitness centers, gyms, sports clubs, and wellness-conscious general public. The company offers bone and muscle diagnostic, bone and muscle research, rehabilitation/physical therapy, sports and fitness, and home products. It serves healthcare, veterinary, and sports and fitness markets in the United States and internationally. The company was formerly known as Norland Medical Systems, Inc. and changed its name to Orthometrix, Inc. in April 2002. Orthometrix, Inc. was founded in 1993 and is headquartered in Naples, Florida.

Orthometrix, Inc. trades as OMRX on OTC. The company is classified in Healthcare / Medical - Specialties and reports in USD.

The current profile places the business in Medical - Specialties. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $1.53M of revenue and $416,149 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Orthometrix, Inc. can be compared against peers such as Acro Biomedical Co., Ltd., ARYx Therapeutics, Inc., AXM Pharma, Inc., Health Discovery Corporation, iBX Group, Inc., Interactive Health Network.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $4,699, beta of -51.49, and return on equity of -16.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

OMRX currently shows total debt of $564,728 and beta of -51.49. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.orthometrix.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.